Prevence osteoporózy - popelka (nejen) české medicíny - editorial

Vladimír Palička

Vnitr Lek 2016, 62(10):768-769  

Magnetická rezonance u kardiomyopatií - editorial

Pavel Gregor

Vnitr Lek 2016, 62(10):770-772  

Hemosuccus pancreaticus - editorial

Jiří Ehrmann, Michal Konečný

Vnitr Lek 2016, 62(10):773-774  

Symptomatic and asymptomatic primary hyperparathyroidism in outpatient care - current issues

Helena Šiprová, Miroslav Souček, Zdeněk Fryšák, Květoslav Šipr

Vnitr Lek 2016, 62(10):775-780  

Objective:To assess the diagnostic and therapeutic options in the care of patients with primary hyperparathyreosis in outpatient practice. Cohort and methods:The study included all the patients with primary hyperparathyroidism treated at the 2^nd Internal Medicine Department, Masaryk University and the University Hospital of St. Anne in Brno in the period from Jan 1, 2008 to Dec 31, 2013. The sample consisted of 218 patients, including 41 men and 177 women. Patients with secondary hyperparathyroidism, especially patients with underlying hypovitaminosis D, renal insufficiency and those taking medications with possible...

Raloxifene - an unexploited possibility of prevention and treatment of postmenopausal osteoporosis

Jan Štěpán, Jan Rosa, Karel Pavelka

Vnitr Lek 2016, 62(10):781-788  

Long-term estrogen deficiency after menopause is responsible for different disorders, which not only make the quality of life in the older age worse but also are the major causes of women's mortality. It is especially the case for cardiovascular disease and osteoporosis. Aim of this review is to point at efficacy of raloxifene (a selective estrogen receptor modulator) in the long-term care of the women in their non-reproductive period of life, and namely in prevention and treatment of postmenopausal osteoporosis.

Treatment of dyslipidemia - is here still place for CETP-inhibitors?

Ján Murín, Miroslav Pernický, Soňa Kiňová

Vnitr Lek 2016, 62(10):789-794  

In the treatment of dyslipidemias about 5-6 years back a new class of drugs emerged, CETP (cholesteryl ester transfer protein)-inhibitors. Their benefit was due to an increase of HDL-cholesterol (HDL-C) serum levels. This treatment mode was supported by epidemiological and clinical studies, as people with high serum HDL-C levels suffered less from cardiovascular (CV) events. Three studies with CETP inhibitors (ILLUMINATE with torcetrapib, dal-OUTCOMES with dalcetrapib and ACCELERATE with evacetrapib) were unfortunately negative, and torcetrapib was even harmful to patients due to an increase of aldosterone serum levels. Treatment with dalcetrapib was...

The benefit of magnetic resonance for diagnosing cardiomyopathy and myocarditis

Michal Fikrle, Petr Kuchynka, Martin Mašek, Jana Podzimková, Jan Kuchař, Aleš Linhart, Tomáš Paleček

Vnitr Lek 2016, 62(10):795-803  

Magnetic resonance is becoming an increasingly used examination in cardiology, since it greatly improves the accuracy of diagnosing of many heart diseases. At present magnetic resonance is the gold standard in assessing the volumes of the heart chambers and the systolic function of both ventricles. The possibility of detecting tissue characteristics to refine the diagnostics of different types of myocardial pathology is of essential importance. The authors summarize in the article the present knowledge about the use of magnetic resonance of the heart in the field of myocardial disease, i.e. cardiomyopathy and myocarditis. The first part of the review...

New - direct oral anticoagulants: actual review

Jana Michalcová, Miroslav Penka, Alena Buliková, Jiřina Zavřelová, Andrea Štěpařová

Vnitr Lek 2016, 62(10):805-813  

In recent years the options of anticoagulant/antithrombotic therapy have extended with new - direct oral anticoagulants, comprising direct thrombin inhibitors (dabigatran etexilate) and direct factor Xa inhibitors (rivaroxaban, apixaban). These agents represent another progress towards "the ideal antithrombotic drug", and thus towards a safe and effective antithrombotic therapy. The following article provides actual review and recommendations for clinical practice, including laboratory assessment and management of emergency situations. The approval of idarucizumab as a specific antidote for dabigatran has marked an important step in safety of this treatment.

Rivaroxaban use in prevention of stroke in patients with non-valvular atrial fibrillation in clinical practice, results of observational studies and our experience

Filip Málek

Vnitr Lek 2016, 62(10):814-819  

Rivaroxaban is direct oral factor Xa inhibitor indicated for tromboembolic event rate reduction in patients with non-valvular atrial fibrillation. Knowledge of rivaroxaban efficacy and safety comes from a phase III randomized clinical trial ROCKET AF. In the present, we have more evidence of rivaroxaban efficacy from real-life clinical studies. XANTUS study was first international prospective observational real-life study documenting use of rivaroxaban in stroke prevention in a broad population of patients with non-valvular atrial fibrillation. The incidence of major bleeding and tromboembolic events was in real clinical practice low. RELIEF study...

Evaluation of five years of treatment of Erdheim-Chester disease with anakinra: case report and overview of literature

Zdeněk Adam, Hana Petrášová, Zdeněk Řehák, Renata Koukalová, Marta Krejčí, Luděk Pour, Eva Vetešníková, Aleš Čermák, Sabina Ševčíková, Petr Szturz, Zdeněk Král, Jiří Mayer

Vnitr Lek 2016, 62(10):820-832  

Erdheim-Chester disease is a histiocytic neoplasm of diseases from the group of non-Langerhans-cell histiocytoses, formed by infiltrates of foamy histiocytes. These pathological histiocytes produce pro-inflammatory cytokines. Therefore Erdheim-Chester disease is called inflammatory histiocytary neoplasm. The disease is accompanied by clinical symptoms of systemic inflammatory response, i.e. B symptoms. Imaging examinations detect typical osteosclerotic changes affecting diaphyses and metaphyses of the lower long bones and fibrotic changes which affect the aorta wall and the vessels leading from it. Also characteristic are perirenal fibrotic changes...

Hemosuccus pancreaticus - rare complication of chronic pancreatitis

Igor Šturdík, Martin Kužma, Zuzana Kužmová, Tomáš Koller, Vladimír Javorka, Tibor Hlavatý, Juraj Payer

Vnitr Lek 2016, 62(10):833-836  

Hemosuccus pancreaticus is a rare cause of upper digestive tract bleeding, it is hemorrhage to the pancreatic duct. A case report is about 56-years old man who was repeatedly hospitalized and suffered from melena and enterorrhagia during 3 years. Imaging studies did not clearly identified etiology of bleeding or source of hemorrhage was wrong identified. Finally, hemosuccus pancreaticus from collaterals of pseudoaneurysm after embolization was suspected because of repeating hemorrhage and embolization of a gastroduodenal artery in history. The interventional procedure was made in a the proximal part of the gastroduodenal artery with a good clinical...

Josef Zadražil, Pavel Horák, David Karásek. Moderní farmakoterapie autoimunitních chorob

Marta Olejárová

Vnitr Lek 2016, 62(10):850  

Arterin - a nutritional supplement in the treatment of dyslipidemia: results of a short-term clinical follow-up study

Miroslav Souček

Vnitr Lek 2016, 62(10):837-840  

Elevated LDL-cholesterol levels are among the main risk factors for ischemic heart disease. It can be influenced by pharmacotherapy, but also by changes in eating and life habits. The most recent recommendations on the treatment of dyslipidemia devote special attention to nutritional supplements and functional foods.

Európsky kardiologický kongres - 1. časť

Ján Murín

Vnitr Lek 2016, 62(10):841-846  

XXIII. kongres České internistické společnosti České lékařské společnosti J. E. Purkyně

Jan Novák

Vnitr Lek 2016, 62(10):847  

52. kongres Európskej asociácie pre štúdium diabetu

Vladimír Uličiansky, Zbynek Schroner

Vnitr Lek 2016, 62(10):848-849